



15 May 2024

**Our Ref:** RFI 57769

**Freedom of Information Act 2000  
Information in Relation to Patients Treated with Durvalumab**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 11 April 2024. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Medicine, Unscheduled Care & Medicine Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Rebecca Manning**  
**Information Governance Officer**

***Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.***

- Q1. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?**
- a. Biliary Tract Cancer**
  - b. Non-Small Cell Lung Cancer**

- A1.** Please see Table 1 for the number of patients treated from November 2023 to March 2024 with Durvalumab for the listed indications.

Table 1

Indications	No. of Patients Treated
Biliary Tract Cancer	Nil
Non-Small Cell Lung Cancer	4

- Q2. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).**

- A2.** There were no patients treated from November 2023 to March 2024 with Nivolumab for early stage Non-Small Cell Lung Cancer (stages 1 – 3b).

- Q3. How many unique total patients were treated last month (March 24) with Durvalumab for the following indications?**
- a. Biliary Tract Cancer**
  - b. Non-Small Cell Lung Cancer**

- A3.** There were no patients treated in March 2024 with Durvalumab for Biliary Tract Cancer or Non-Small Cell Lung Cancer.

- Q4. How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?**
- a. Biliary Tract Cancer**
  - b. Non-Small Cell Lung Cancer**

- A4.** Please see Table 2 for the number of patients who received their first treatment between November 2023 and March 2024 with Durvalumab for the listed indications.

Table 2

Indications	No. of Patients Treated
Biliary Tract Cancer	Nil
Non-Small Cell Lung Cancer	1